



**NEWRON COMPLETES RECRUITMENT FOR
RALFINAMIDE PHASE II MTD STUDY
IN NEUROPATHIC PAIN**

Milan, Italy – MARCH 8, 2007 - Newron Pharmaceuticals S.p.A. ("Newron"), a research and development company focused on novel CNS therapies, announces the completion of enrollment in its Phase II, double-blind, randomized, placebo controlled, multi-national study of ralfinamide in patients with neuropathic pain. Two hundred-fifty-nine patients affected by at least moderate neuropathic pain associated with Diabetic Neuropathy, Post-herpetic Neuralgia, Post-Surgical Neuralgia, Trigeminal Neuralgia, etc., diagnosed in accordance with the diagnostic criteria proposed by the International Association for Study of Pain, have been enrolled in Austria, the Czech Republic, India, Italy, Poland, and the UK in this 8-week treatment trial.

Ralfinamide is a unique New Chemical Entity that combines use and frequency dependent inhibition of sodium channels present on sensory neurons and blockade of calcium ion flow, believed to be implicated in the pathogenesis of neuropathic pain. Newron's Chief Medical Officer, Ravi Anand, M.D., commented on the strategic importance of the study in the further development of the compound: "This study includes various sub-types of neuropathic pain patients and, using multiple assessment measures, should determine the type of neuropathic pain that is most responsive to ralfinamide. Alongside, the study will determine the dose range of the drug that will be evaluated in future efficacy and safety trials".

The company is on schedule to announce the results of this safety, tolerability, and preliminary evidence of efficacy trial by end of June 2007.

About Newron Pharmaceuticals

Newron Pharmaceuticals S.p.A. (www.newron.com) is a biopharmaceutical company focused on novel therapies for diseases of the Central Nervous System, particularly Parkinson's disease (PD) and pain. Newron is undertaking phase III trials with safinamide, a unique molecule with multiple mechanisms of action, for the treatment of PD in conjunction with its partner, Merck Serono, which has the rights to

develop the compound in PD, Alzheimer’s disease, other cognitive disorders and Restless Legs Syndrome. Recent results of a six-month phase III trial of safinamide in PD demonstrated its benefit in motor symptoms and activities of daily living, as well as its improvement in cognitive function and good tolerability. Newron and Merck Serono are planning to expand the development of safinamide to exploit its potential in Alzheimer’s disease. Phase II trials with safinamide in Restless Legs Syndrome have shown promising results. Newron is also conducting phase II trials with ralfinamide for the treatment of neuropathic pain. The drug has potential benefit in inflammatory pain, as well. Newron’s clinical pipeline is supported by a portfolio of early-stage proprietary compounds generated by its ion channel drug discovery platform. Newron is headquartered in Bresso, near Milan, Italy. The company is listed at SWX Swiss Exchange, trading symbol NWRN.

About ralfinamide

Ralfinamide is a potent voltage- and use-dependent Ion channel blocker that showed good activity in several animal models of chronic pain. In addition, it has shown promising results in a pilot Phase II clinical trial: Ralfinamide was well tolerated up to the maximal dose without the occurrence of any consistent pattern of clinically-relevant adverse change in vital signs, ECG and other laboratory values. It showed beneficial effects on symptoms and severity of pain.

For more information, contact:

Media	Investors and analysts
<p>Italy Luca Benatti - CEO Phone: +39 02 6103 4 626</p> <p>UK/Global media Julia Phillips Financial Dynamics Phone: +44 (0) 20 7269 7187</p> <p>Switzerland Martin Meier-Pfister The Investor Relations Firm AG Phone: +41 43 244 81 40</p>	<p>Stefan Weber - CFO Phone: +39 02 6103 46 30</p>

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Newron undertakes no obligation to publicly update or revise any forward-looking statements.